Fig. 5.

The effects of doxorubicin-loaded immunolipoplex on tumor growth in vivo. a The inhibition of Dox/LPPC/Herceptin on tumor growth. NOD-SCID mice bearing SKBR-3 cells were treated on day 6 with either Dox/LPPC/Rituximab (5 mg/kg Dox and 4 mg/kg Rituximab), Dox/LPPC/Herceptin (5 mg/kg Dox and 4 mg/kg Herceptin), Dox-H/LPPC/Herceptin (50 mg/kg Dox and 4 mg/kg Herceptin) or 5 mg/kg LipoDox by i.v. injection once a week. The tumor volumes were measured every 2 days after treatment. All values represent the mean ± SD (n = 8). b The tumors of the mice with different treatments were removed and are shown at day 16. c The tumor sizes of the mice after treatment with Dox/LPPC/Herceptin are shown at days 6 and 20. Each color represents an individual treated mouse (n = 12). d Mouse survival was monitored daily. The mice were sacrificed when the tumor sizes exceeded 2500 mm³. e Mice bearing SKBR-3 cells were treated with LipoDox plus either Herceptin or Dox/LPPC/Herceptin. The mice were scarified at different time points after treatment and the pathologic changes in tumors were examined by H&E staining and observed using a light microscope (×400). The distribution of doxorubicin within the tumors was imaged using a fluorescent light microscope (×400)